1. Home
  2. GLPG vs NTCT Comparison

GLPG vs NTCT Comparison

Compare GLPG & NTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$32.32

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

HOLD

Current Price

$28.07

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
NTCT
Founded
1999
1984
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2005
1999

Fundamental Metrics

Financial Performance
Metric
GLPG
NTCT
Price
$32.32
$28.07
Analyst Decision
Hold
Buy
Analyst Count
4
2
Target Price
$31.33
$32.00
AVG Volume (30 Days)
86.3K
598.8K
Earning Date
11-05-2025
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.24
Revenue
$336,643,201.00
$862,770,000.00
Revenue This Year
$3.61
$5.90
Revenue Next Year
N/A
$2.62
P/E Ratio
N/A
$22.69
Revenue Growth
10.31
9.60
52 Week Low
$22.36
$18.12
52 Week High
$37.78
$30.67

Technical Indicators

Market Signals
Indicator
GLPG
NTCT
Relative Strength Index (RSI) 56.94 58.58
Support Level $30.73 $26.83
Resistance Level $32.75 $27.92
Average True Range (ATR) 0.60 0.59
MACD 0.07 0.07
Stochastic Oscillator 78.52 92.02

Price Performance

Historical Comparison
GLPG
NTCT

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

Share on Social Networks: